Share on LinkedInShare on LinkedIn

ARTICLE · 26 FEBRUARY 2025

A Stratification Too Far? How The CNIPA Draws The Line On Patient Subgroups In A Recent Precision Medicine Invalidation Case

A recent CNIPA invalidation case examines how precision medicine patents are evaluated in China, specifically addressing whether patient stratification based on biomarkers like serum alkaline phosphatase levels constitutes valid claim limitations. The decision provides critical guidance on what evidence is required to establish new patient subgroups and how disease markers must demonstrate clinical guidance value to support inventive step arguments.

ChinaIntellectual Property

Precision medicine is rapidly transforming the global healthcare landscape, providing more effective therapies and better patient outcomes through targeted solutions. As therapeutics move away from the traditional “one-size-fits-all” model, unique challenges are presented in the patent examination process.

The 2024 Top 10 Patent Re-examination and Invalidation case highlighted below provides further insight into how the China National Intellectual Property Administration (CNIPA) interprets claim scope and inventive step during the examination of precision medicine technologies.

Background

Generic Drug maker Chia Tai Tianqing Pharmaceutical Group filed an invalidation request before the Patent Re-examination Board (the “Board”) against an invention patent titled "Use of Degarelix1 in the Preparation of a Medicament for Treating Metastatic Prostate Cancer"2, owned by Ferring International Pharma (Switzerland), on the basis of lack of inventiveness.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from